The Campaign for Sustainable Rx Pricing released the following statement applauding Senators Leahy, Grassley, Feinstein, Klobuchar, and Lee, and Representatives Marino and Cicilline for the introduction of the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act:
“Big Pharma’s longstanding pattern of utilizing the REMS process to forestall generic and biosimilar medications from reaching patients is an anticompetitive and cynical abuse of an important tool for patient safety.
“It is absolutely critical to ensure that medications are utilized safely by those who use them, but it is also enormously important to ensure that medications are affordable to those who need them. The CREATES Act represents market-based reforms that will increase competition and ensure that lifesaving medications can safely reach patients at an affordable price.”
– Will Holley – CSRxP Spokesman